July 20, 2011
Stopping Early Menopause in Cancer Patients
(Ivanhoe Newswire) -- Temporarily suppressing ovarian function with use of the hormone analogue triptorelin reduced the occurrence of early menopause induced by chemotherapy among women with breast cancer, according to this study.
Approximately 6 percent of women with breast cancer are diagnosed before age 40 years, with the majority of young patients receiving systemic treatment with chemotherapy, hormonal therapy, or both. Chemotherapy regimens are associated with an incidence of long-term amenorrhea (absence of menstruation) of at least 40 percent, according to background information in the article. No standard strategies for preventing chemotherapy-induced ovarian failure are yet available. Preclinical data have suggested that temporary ovarian suppression with a gonadotropin (hormones that are secreted by the pituitary gland)-releasing hormone (GnRH) analogue (chemical compound) during chemotherapy reduces ovarian toxicity.
Lucia Del Mastro, M.D., of the Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, and colleagues conducted a phase 3 trial designed to assess the efficacy of temporary ovarian suppression induced by the GnRH analogue triptorelin in reducing the incidence of early menopause in young women with breast cancer undergoing supplemental or neoadjuvant (i.e., administered before surgery for breast cancer) chemotherapy. The randomized trial was conducted at 16 sites in Italy and enrolled 281 patients between October 2003 and January 2008. The patients were premenopausal women with stage I through III breast cancer who were candidates for adjuvant or neoadjuvant chemotherapy. Before beginning chemotherapy, patients were randomly allocated to receive chemotherapy alone or combined with triptorelin, which was administered intramuscularly at least 1 week before the start of chemotherapy and then every 4 weeks for the duration of chemotherapy.
Resumption of menses was observed in 60 patients in the chemotherapy-alone group (49.6 percent) and in 88 in the chemotherapy plus triptorelin group (63.3 percent).
"In conclusion, our results suggest that temporarily suppressing ovarian function by administering triptorelin reduces the incidence of chemotherapy-induced early menopause. This treatment can therefore be offered to premenopausal patients with breast cancer who wish to decrease the risk of permanent ovarian failure associated with chemotherapy," the authors were quoted as saying.
SOURCE: JAMA, published online July 18, 2011